A second RLR agonist, 3p-125b-ASO, also was engineered to silence the oncogene miR-125b, and i.t. delivery of 3p-125b-ASO in RBC-derived EVs following the same schedule as immRNA RBC-derived EVs also led to a reduction in tumor growth, increase in i.t. neutrophils, macrophages, DCs, NK cells, and T cells, increase in i.t. pro-inflammatory cytokines (TNFα, IL-6, IL-12p40), and increase in apoptosis (142). This evidence concerns the gene TNF and neoplasm.